Effect of omega-3-acid ethyl esters on steady-state plasma pharmacokinetics of atorvastatin in healthy adults

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 17, 2008, Pages 2939-2945

  Di Spirito, Mike ^a   Morelli, G ^a   Doyle, R T ^a   Johnson, J ^a   McKenney, J ^a  

^a MDS Inc   (Canada)

Author keywords

Atorvastatin; Bioavailability; Pharmacokinetics; Prescription omega 3 acid ethyl esters

Indexed keywords

2 HYDROXYATORVASTATIN; 4 HYDROXYATORVASTATIN; ATORVASTATIN; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; FEMALE; FLATULENCE; HUMAN; HUMAN EXPERIMENT; LIMB PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORNING DOSAGE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; STEADY STATE;

ADULT; FATTY ACIDS, OMEGA-3; FEMALE; HEALTH; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; PYRROLES;

EID: 57549108116     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560802233827     Document Type: Article

References (17)

1. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
2. Hopkins PN, Wu LL, Hunt SC, et al. Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. J Am Coll Cardiol 2005;45:1003-12
3. Maire I, Belmatoug N. Fabry's disease. Presse Med 2007;36:69-70
4. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
5. Nambi V, Ballantyne CM. Combination therapy with statins and omega-3 fatty acids. Am J Cardiol 2006;98:34i-38i
6. Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 1998;82:74U-81U
7. Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett 2002;128:159-68
8. Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 1997;4:385-91
9. Calabresi L, Donati D, Pazzucconi F, et al. Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis 2000;148:387-96
10. Davidson MH, Stein EA, Bays HE, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 2007;29:1354-67
11. Betteridge DJ, Durrington PN, Fairhurst GJ, et al. Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia. Am J Med 1994;96:45S-54S
12. Lins RL, Matthys KE, Verpooten GA, et al. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephrol Dial Transplant 2003;18:967-76
13. US Department of Health and Human Services. Guidance for industry: drug interaction studies - study design, data analysis, and implications for dosing and labeling; 2006
14. McKenney JM, Swearingen D, Di SM, et al. Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters. J Clin Pharmacol 2006;46:785-91
15. Pharmacokinetic interaction study between prescription omega-3-acid ethyl esters (P-OM3) and rosuvastatin in healthy subjects. Biennial International Congress on Coronary Artery Disease; Venice, Italy; 7-10 October 2007
16. Durrington PN, Bhatnagar D, Macknees MI, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 2001;85:544-8
17. Reliant Pharmaceuticals. Evaluation of efficacy and safety of Omacor, co-administered with atorvastatin, in subjects with hypertriglyceridemia. Available from: http://www.clinicaltrials.gov/ct2/ show/NCT00435045 [Accessed 25 June 2008]